

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

25 Jun 2026

### In vivo Bioequivalence study of Aspirin 81mg tablet manufactured by Aani Darman Pharmaceutical Co. Compared to innovator Product

#### Protocol summary

##### Study aim

In vivo fasted-state bioequivalence study of Aspirin 81 mg tablet

##### Design

The clinical trial has control and test groups with crossover, randomized design, without blinding. 24 healthy male volunteers will participate randomly in the study as two twelve-person groups. Each volunteer will receive a single dose in two periods. In one period the test and in another period the reference formulation. Therefore, each volunteer will be his own "Control". To randomly assign participants in two groups, the lottery method will be used.

##### Settings and conduct

After oral administration of one 81-mg tablet to volunteer, the blood samples will be collected in predetermined time intervals up to 24 hours. The samples will be stored in freezer -4 degrees centigrade until analysis and sample quantitation. The concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector. The study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: General Health (in terms of Liver, Heart and Kidney diseases), Age (18-59 years old) Exclusion criteria: Smoking, History of cardiovascular disease, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy

##### Intervention groups

Intervention group will receive a single oral dose of test drug product (Aspirin 81 mg tablet manufactured by Aani Darman, Iran) and Control group will receive a single dose of reference drug product (Aspirin 81 mg tablet manufactured by Bayer, USA). Blood samples will be taken from the volunteers for 24 hours at the mentioned time points after drug administration and the plasma will be stored in freezer until analysis. In both groups, breakfast and lunch will be served two and six hours

after drug administration, respectively).

##### Main outcome variables

Drug plasma concentration

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220211053992N6**

Registration date: **2023-01-09, 1401/10/19**

Registration timing: **prospective**

Last update: **2023-01-09, 1401/10/19**

Update count: **0**

##### Registration date

2023-01-09, 1401/10/19

##### Registrant information

##### Name

Hadi Valizadeh

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 3334 8801

##### Email address

valizadehh@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-01-10, 1401/10/20

##### Expected recruitment end date

2023-03-20, 1401/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
In vivo Bioequivalence study of Aspirin 81mg tablet manufactured by Aani Darman Pharmaceutical Co. Compared to innovator Product

**Public title**  
In vivo Bioequivalence study of Aspirin tablet

**Purpose**  
Other

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
General Health (in terms of Liver, Heart and Kidney diseases) Age between 18 to 60 years  
**Exclusion criteria:**  
Smoking, History of cardiovascular, liver, and kidney disease Pregnancy Alcohol and drug addiction History of drug allergy

**Age**  
From **18 years** old to **59 years** old

**Gender**  
Male

**Phase**  
Bioequivalence

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **24**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.

**Blinding (investigator's opinion)**  
Not blinded

**Blinding description**

**Placebo**  
Not used

**Assignment**  
Crossover

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Biomedical Research Committe, Tabriz University of

Medical Sciences

**Street address**  
Faculty of Pharmacy, University of Medical Sciences, Golgasht st Attar Neishaboori st. Tabriz University of Medical Sciences

**City**  
Tabriz

**Province**  
East Azarbaijan

**Postal code**  
51664-14766

**Approval date**  
2022-12-19, 1401/09/28

**Ethics committee reference number**  
IR.TBZMED.REC.1401.855

## Health conditions studied

### 1

#### Description of health condition studied

In the present study, the products will be administered to healthy volunteers.

#### ICD-10 code

#### ICD-10 code description

## Primary outcomes

### 1

#### Description

Plasma concentration of drug

#### Timepoint

0.5-24 hours in predetermined time intervals after drug administration

#### Method of measurement

HPLC (High performance liquid chromatography)

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Intervention group will receive a single oral dose of test product (Aspirin 81mg sachet manufactured by Aani Darman Co., Iran) in fasted state. Blood samples will be collected for 24 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Control group will receive a single oral

dose of reference product (Aspirin 81mg tablet manufactured by Bayer, USA) in fasted state. Blood samples will be collected for 24 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Tabriz University of Medical Sciences, Faculty of Pharmacy

**Full name of responsible person**

Hadi Valizadeh

**Street address**

Faculty of Pharmacy, University of Medical Sciences, Attar Neishaboori st., Golgasht st.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51664-14766

**Phone**

+98 41 3334 8801

**Fax**

+98 41 3334 4798

**Email**

valizadehh@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Parviz Shahabi

**Street address**

No.2 Central Building 3rd Floor, University of Medical Sciences, Daneshgah st.

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51664-14766

**Phone**

+98 41 3334 8801

**Fax**

+98 41 3334 4798

**Email**

shahabip@tbzmed.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Aani Darman Pharmaceutical Company

**Proportion provided by this source**

100

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Industry

**Person responsible for general inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hadi Valizadeh

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Faculty of Pharmacy, University of Medical Sciences, Golgasht st Attar Neishaboori st. Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51664-14766

**Phone**

+98 41 3334 8801

**Email**

valizadehh@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hadi Valizadeh

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Faculty of Pharmacy, University of Medical Sciences, Golgasht st Attar Neishaboori st. Tabriz

University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51664-14766

**Phone**

+98 41 3334 8801

**Email**

valizadehh@gmail.com

Tabriz

**Province**

East Azarbaijan

**Postal code**

51664-14766

**Phone**

+98 41 3334 8801

**Email**

valizadehh@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hadi Valizadeh

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Faculty of Pharmacy, University of Medical Sciences,  
Golgasht st Attar Neishaboori st. Tabriz University of  
Medical Sciences

**City**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Not applicable

### Data Dictionary

Not applicable